Trial Profile
Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG (VisAcT), a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Cancer Patients Who Have Received or Are Expected to Receive Immunotherapy and/or Radiation Therapy
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Aug 2021
Price :
$35
*
At a glance
- Drugs 18F-F-AraG (Primary)
- Indications Cancer
- Focus Diagnostic use
- Sponsors CellSight Technologies
- 02 Aug 2021 Planned End Date changed from 1 May 2021 to 1 May 2024.
- 02 Aug 2021 Planned primary completion date changed from 1 May 2021 to 1 May 2024.
- 13 Jul 2020 Planned primary completion date changed from 1 May 2020 to 1 May 2021.